Single dose systemic acetaminophen to improve patient reported quality of recovery after ambulatory segmental mastectomy: A prospective, randomized, double-blinded, placebo controlled, clinical trial

2017 ◽  
Vol 24 (3) ◽  
pp. 240-244 ◽  
Author(s):  
Gildasio S. De Oliveira ◽  
Meghan E. Rodes ◽  
Jane Bialek ◽  
Mark C. Kendall ◽  
Robert J. McCarthy
Keyword(s):  
Clinical Trial ◽  
Single Dose ◽  
Controlled Clinical Trial ◽  
Quality Of Recovery ◽  
Patient Reported ◽  
Segmental Mastectomy ◽  
Double Blinded ◽  
Improve Patient

The effect of methadone on postoperative quality of recovery in patients undergoing laparoscopic cholecystectomy: A prospective, randomized, double blinded, controlled clinical trial

2019 ◽  
Vol 53 ◽  
pp. 64-69 ◽  
Author(s):  
Eduardo T. Moro ◽  
Miller F. Lambert ◽  
Ana Luiza Pereira ◽  
Thaís Artioli ◽  
Giuliana Graicer ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Laparoscopic Cholecystectomy ◽  
Controlled Clinical Trial ◽  
Quality Of Recovery ◽  
Double Blinded ◽  
Postoperative Quality

scholarly journals Single postoperative infusion of zoledronic acid to improve patient-reported outcome after hip or knee replacement: study protocol for a randomised, controlled, double-blinded clinical trial

BMJ Open ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. e040985
Author(s):  
Jonathan Brandt ◽  
Håkan Ledin ◽  
Jonas Ranstam ◽  
Ewa Roos ◽  
Per Aspenberg ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Zoledronic Acid ◽  
Knee Replacement ◽  
Knee Prosthesis ◽  
Patient Reported Outcome ◽  
Ethical Review ◽  
Outcome Score ◽  
Patient Reported ◽  
Double Blinded ◽  
Improve Patient

IntroductionIn Sweden, roughly 3000 patients are reoperated each year due to pain and loss of function related to a loosened hip or knee prosthesis. These reoperations are strenuous for the patient, technically demanding and costly for the healthcare system. Any such reoperation that can be prevented would be of great benefit. Bisphosphonates are drugs that inhibit osteoclast function. Several clinical trials suggest that bisphosphonates lead to improved implant fixation and one small study even indicates better functional outcome. Furthermore, in epidemiological studies, bisphosphonates have been shown to decrease the rate of revision for aseptic loosening by half. Thus, there are several indirect indications that bisphosphonates could improve patient-reported outcome, but no firm evidence.Methods and analysisThis is a pragmatic randomised, placebo-controlled, double-blinded, academic clinical trial of a single postoperative dose of zoledronic acid, in patients younger than 80 years undergoing primary total hip or knee replacement for osteoarthritis. Participants will be recruited from two orthopaedic departments. All surgeries will be performed, and study drugs given at Motala Hospital, Sweden. The primary endpoint is to investigate between-group differences in the Hip dysfunction and Osteoarthritis Outcome Score and the Knee injury and Osteoarthritis Outcome Score at 3-year follow-up. Secondary outcomes will be investigated at 1 year, 3 years and 6 years, and stratified for hip and knee implants. These secondary endpoints are supportive, exploratory or explanatory. A total of 1000 patients will be included in the study.Ethics and disseminationThe study has been approved by the Regional Ethical Review Board in Linköping (DNR 2015/286-31). The study will be reported in accordance with the Consolidated Standards of Reporting Trials statement for pharmacological trials. The results will be submitted for publication in peer-reviewed academic journals and disseminated to patient organisations and the media.Trial registration numberEudraCT: No 2015-001200-55; Pre-results.

The Effectiveness of Combination of Viola odorata L., Rosa damascena Mill. and Coriandrum sativum L. on Quality of Life of Patients with Migraine Headaches: A Randomized, Double Blinded, Placebo - Controlled Clinical Trial

2019 ◽  
Author(s):  
Mohadese Kamali ◽  
Haleh Tajadini ◽  
Rostam Seifadini ◽  
Mitra Mehrabani ◽  
Yunes Jahani ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Trial ◽  
Coriandrum Sativum ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
Rosa Damascena ◽  
Viola Odorata ◽  
Migraine Headaches ◽  
Double Blinded

Headache is one of the most common public health problems in the world, which causes patients to see a doctor. Migraine is the second most common cause of headaches after tension headaches. This study is a randomized, double blinded, placebo - controlled clinical trial, using SF36 questionnaire, to evaluate the effect of combination of Viola odorata L., Rosa damascena Mill. and Coriandrum sativum L. on the quality of life, in patients with migraine after 4 weeks. In all domains of the SF36 questionnaire, the scores after intervention in the drug group were significantly higher than the control group after 4 weeks. This study showed that, combination of V. odorata, R. damascena and C. sativum, improves the quality of life of patients with migraine.

Quality of Life Increased After Treatment for Participants in a Phase 2B Randomized, Double-Blinded, Placebo-Controlled Clinical Trial of RBX2660 for Preventing Recurrent Clostridium difficile Infections

2018 ◽  
Vol 113 (Supplement) ◽  
pp. S1524
Author(s):  
Beth Guthmueller ◽  
Robert Orenstein ◽  
Erik Dubberke ◽  
Sahil Khanna ◽  
Dale Gerding ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Trial ◽  
Clostridium Difficile ◽  
Controlled Clinical Trial ◽  
Double Blinded

scholarly journals The Effect of Lactobacillus acidophilus YT1 (MENOLACTO) on Improving Menopausal Symptoms: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial

2020 ◽  
Vol 9 (7) ◽  
pp. 2173
Author(s):  
Eun Yeong Lim ◽  
So-Young Lee ◽  
Hee Soon Shin ◽  
Jaekwang Lee ◽  
Young-Do Nam ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Trial ◽  
Lactobacillus Acidophilus ◽  
Menopausal Symptoms ◽  
Controlled Clinical Trial ◽  
Life Questionnaire ◽  
Sexual Symptoms ◽  
Significant Difference ◽  
Double Blinded

This study evaluated the efficacy of Lactobacillus acidophilus YT1 (MENOLACTO) for alleviating menopausal symptoms. This study was a multi-center, randomized, double-blinded, placebo-controlled clinical trial involving female subjects (ages: 40–60 years) with menopausal symptoms and a Kupperman index (KMI) score ≥ 20. Subjects were administered 1 × 108 CFU/day MENOLACTO or placebo, with the primary endpoint being total KMI score, and the effect of secondary endpoints on alleviating menopausal symptoms according to individual categories of the modified KMI, as well as a quality of life questionnaire (MENQOL questionnaire). After 12 weeks, total KMI scores decreased significantly, demonstrating improved menopausal symptoms relative to placebo along with improved modified KMI scores. Additionally, quality of life, according to the MENQOL questionnaire, significantly improved in all four symptoms—physical, psychosocial, vasomotor, and sexual symptoms. Moreover, we observed no significant difference between the two groups or significant changes in blood follicle-stimulating hormone and estradiol levels or endometrial thickness. These results demonstrated that MENOLACTO alleviated menopausal symptoms without notable side effects and improved quality of life, suggesting its efficacy as an alternative supplement to alleviate menopausal symptoms in women ineligible for hormonal therapy.

Sign in / Sign up

Export Citation Format

Share Document